Would you provide abemaciclib to a premenopausal women with cT2 cN1 ER+ breast cancer and Ki67 of 80% who achieves pCR following neoadjuvant AC-T?

Patients who received neoadjuvant Chemotherapy were only eligible for the trial if they had residual disease above a threshold quantified using CPS-EG.